Skip Navigation



NDT Advance Access published online on October 12, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfi197
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/2/494    most recent
gfi197v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Furuya, R.
Right arrow Articles by Hishida, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Furuya, R.
Right arrow Articles by Hishida, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received May 12, 2005
Accepted September 9, 2005

Original Articles

Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients

Ryuichi Furuya 1*, Mari Odamaki 2, Hiromichi Kumagai 2, and Akira Hishida 3

1 Department of Internal Medicine, Iwata City Hospital, Iwata, Japan
2 Department of Clinical Nutrition, School of Food and Nutritional Sciences, University of Shizuoka, Shizuoka, Japan
3 First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

* To whom correspondence should be addressed.
Ryuichi Furuya, E-mail: r-furuya{at}isis.ocn.ne.jp



  Abstract

Objective. Leptin and adiponectin, well-recognized adipocytokines, are reported to contribute to the pathogenesis of atherosclerosis. The aim of this study was to elucidate the effects of icodextrin-based dialysis solution on adipocytokine metabolism.

Methods. In 12 non-diabetic anuric patients on peritoneal dialysis, dialysis solution was changed from glucose-based dialysis solution to icodextrin-based dialysis solution for 6 months. Plasma levels of leptin, adiponectin, lipids (total cholesterol, HDL-cholesterol and triglyceride), insulin, blood glucose and insulin sensitivity index by the homeostasis model assessment (HOMA-IR) were compared before and after the use of the icodextrin solution.

Results. Plasma leptin level was decreased from 15.6 (2.5-69.0) to 7.3 (2.9-45.9) ng/ml (P = 0.018) and plasma adiponectin level increased from 11.6 (6.2-19.6) to 17.6 (7.8-33.0) µg/ml (P = 0.002). A reduction in plasma insulin level from 33.1 (13.8-54.1) to 19.1 (5.8-37.3) µU/ml (P = 0.009) and HOMA-IR from 8.22 (3.68-15.09) to 5.15 (1.40-13.78) (P = 0.015) was observed. While plasma total cholesterol level remained similar, HDL-cholesterol level increased, from 36.0 (22-45) to 43.5 (30-69) mg/dl (P = 0.008) and the triglyceride level decreased, from 174.0 (140-250) to 116.5 (81-207) mg/dl (P = 0.012).

Conclusion. Icodextrin-based dialysis solution improves abnormal adipocytokine metabolism, dyslipidaemia and insulin resistance, which are known to be associated with atherosclerosis. These results suggest that the use of icodextrin-based dialysis solution might be useful in preventing atherosclerosis in PD patients. Long-term effects of icodextrin-based dialysis solution on the atherosclerosis in peritoneal dialysis patients should be tested.

Keywords: adiponectin; dyslipidaemia; icodextrin; insulin resistance; leptin; peritoneal dialysis.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
A. Lin, J. Qian, X. Li, X. Yu, W. Liu, Y. Sun, N. Chen, C. Mei, and for the Icodextrin National Multi-center Cooperati
Randomized Controlled Trial of Icodextrin versus Glucose Containing Peritoneal Dialysis Fluid
Clin. J. Am. Soc. Nephrol., November 1, 2009; 4(11): 1799 - 1804.
[Abstract] [Full Text] [PDF]

Home page
 pdiHome page
J.-H. Liu, H.-H. Lin, Y.-F. Yang, Y.-L. Liu, H.-L. Kuo, I-K. Wang, C.-Y. Chou, and C.-C. Huang
SUBCLINICAL PERIPHERAL ARTERY DISEASE IN PATIENTS UNDERGOING PERITONEAL DIALYSIS: RISK FACTORS AND OUTCOME
Perit. Dial. Int., January 1, 2009; 29(1): 64 - 71.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
C. J. Holmes and W. Smit
Future technologies and techniques in peritoneal dialysis--opportunities and challenges ahead
NDT Plus, October 1, 2008; 1(suppl_4): iv51 - iv55.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. J. Davies, E. G. Lopez, G. Woodrow, K. Donovan, J. Plum, P. Williams, A. C. Johansson, H.-P. Bosselmann, O. Heimburger, O. Simonsen, et al.
Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2982 - 2988.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. B. McCormick and J. M. Bargman
Noninfectious Complications of Peritoneal Dialysis: Implications for Patient and Technique Survival
J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3023 - 3025.
[Abstract] [Full Text] [PDF]

Home page
 pdiHome page
Y.-L. Kim
CAN WE OVERCOME THE PREDESTINED POOR SURVIVAL OF DIABETIC PATIENTS? PERSPECTIVES FROM PRE- AND POST-DIALYSIS
Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S171 - S175.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.